Datar Cancer Genetics Launches AI-Powered Platform for Personalized Cancer Treatment

The platform suggests up to 10 evidence-based multi-drug combinations that can be considered by oncologists and molecular tumor boards (MTBs).

Maharashtra-based diagnostic center Datar Cancer Genetics (DCG) has unveiled Exacta AI, an artificial intelligence-powered multi-analyte platform designed to optimize cancer treatment.

By integrating molecular, proteomic, genomic, functional, and clinical data, the platform uses AI-assisted analysis to generate personalized, evidence-based treatment strategies for patients.

The AI-driven system evaluates drug synergy, interactions, toxicity, and contraindications across a wide range of therapies, including antibody-drug conjugates (ADCs), checkpoint inhibitors (CPIs), targeted therapies, endocrine agents, chemotherapy, and repurposed drugs.

Oncologists and molecular tumor boards (MTBs) can consider up to 10 evidence-based multi-drug combinations suggested by the platform.

Enhancing Oncologists' Decision-Making

Highlighting the platform’s potential, Dr. Sewanti Limaye, Director of Medical and Precision Oncology at Sir HN Reliance Foundation Hospital, emphasized its ability to revolutionize personalized cancer treatment.

Dr Darshana Patil, Senior Director for Global Strategy and Medical Affairs at DCG, pointed out that Exacta AI addresses a critical challenge in oncology—managing large volumes of clinical and molecular data.

“When standard treatments fail, oncologists and MTBs must analyze massive datasets while racing against time. Exacta AI transforms this challenge into an opportunity for precision medicine,” she said.

The platform enhances MTB workflows by offering structured case analyses, evidence-based treatment options, and references to similar reported cases.

Future of AI in Cancer Treatment

Now available for cancer centers and hospitals, Exacta AI offers seamless integration, training, and ongoing support.

Dr Andy Gaya, a clinical oncologist at The Cromwell Hospital, London, emphasized that AI-driven platforms like Exacta AI offer an unprecedented level of therapy analysis, helping to improve patient outcomes while reducing ineffective treatments.

In a retrospective study of 265 patients with drug-resistant solid organ cancers, Exacta AI provided at least seven therapy options per patient.

In contrast, conventional molecular profiling yielded only two options for 15% of patients, demonstrating the platform’s ability to expand treatment possibilities.

Dr Vineet Datta, Senior Director for Global Strategy and Business Development at DCG, explained that Exacta AI functions like a multidisciplinary expert team, processing data within minutes instead of days.

Stay tuned for more such updates on Digital Health News.